1. Introduction {#s0005}
===============

Coronary artery disease is a multifactorial cardiovascular disease whose manifestation is often influenced by the presence of several risk traits including hypertension (HTN) and type 2 diabetes mellitus (T2DM) and dyslipidaemic disorders. Several studies have indicated that CAD may share common predisposing genetic variants with these risk traits particularly HTN and T2DM. One of the loci that has been linked with CAD thus far is the cyclin-dependent kinase (CDK) 4 inhibitor B, also known as multiple suppressor 2 or p15, a protein that is encoded by the cyclin-dependent kinase 2B (*CDKN2B*) gene in humans ([@b0210]). This protein is a cell growth regulator that inhibits the cell cycle G1 progression by forming a complex with CDK4 or CDK6 thereby prevent the activation of the CDKs by cyclin D ([@b0070]). The *CDKN2B* gene itself is located within the p.14- p.16 gene cluster at 9p21 locus. Apart from CAD, this gene cluster harbours several genes implicated in various other disorders, such as, coronary artery disease, changes in lipid levels, coronary microvascular dysfunction, diabetes, cancer and periodontitis in different ethnic populations ([@b0225], [@b0265], [@b0075], [@b0130], [@b0220], [@b0240], [@b0105], [@b0230], [@b0245], [@b0005], [@b0020], [@b0045], [@b0060], [@b0065], [@b0080], [@b0085], [@b0100], [@b0120], [@b0135], [@b0145], [@b0170], [@b0195], [@b0205], [@b0215], [@b0175]). Specifically, a recent genome-wise study by [@b0225] has illustrated through a genome-wide association study (GWAS) that several variants at the *CDKN2B* locus that were implicated in CAD/MI, but also suggestive of constituting similar risk for HTN or T2DM in ethnic Saudi Arabs ([@b0225]). While some studies have associated this gene with T2DM ([@b0165], [@b0050]), other have failed to verify the observations, pointing to the fact that the role of the *CDKN2B* gene locus in the cardiovascular disease traits a still not well defined ([@b0025], [@b0055]). Hence, their actual impact of these traits on the latter requires to be validated through replication studies. Besides, since most of the identified variants are believed to constitute simply representatives for other functional ones, the actual causative entities remain to be fully characterized. In the present study, we elected to verify the possibility of the *CDKN2B* genomic region being a risk factor for T2DM or HTN in this ethnic population.

2. Methodology {#s0010}
==============

2.1. Study population {#s0015}
---------------------

The study population comprised a total of 4650 Saudi individuals ([Table 1](#t0005){ref-type="table"}). Among these, 2576 (1728 male; 848 female) individuals had type 2 diabetes mellitus (T2DM) (formerly called non-insulin-dependent diabetes mellitus or adult onset diabetes) compared 2074 (1316 male; 758 female) individuals free of the disease ([Table 1](#t0005){ref-type="table"}). The USA National Diabetes Data Group and the second World Health Organization (WHO) Expert Committee on Diabetes Mellitus (1998) defines type 2 diabetes mellitus as a metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency ([@b0015]). The second subset of interest comprised 3732 (2451 male; 1281 female) candidates with primary (essential) hypertension (HTN) compared with 918 (593 male; 325 female) non-hypertensive controls ([Table 2](#t0010){ref-type="table"}). Hypertension was defined and classified as ≥140 Hg systolic blood pressure and ≥90 Hg diastolic pressure based on criteria of The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Accordingly, essential, primary, or idiopathic hypertension is defined as high blood pressure (BP) in which secondary causes such as renovascular disease, renal failure, pheochromocytoma, aldosteronism, or other causes of secondary hypertension or Mendelian forms (monogenic) are not present ([@b0035]). The study population was derived from a national CAD registry cohort, hence some of the individuals may have carried the disease. Individuals were excluded from the study population if they were diagnosed with major cardiac rhythm disturbances, incapacitating or life-threatening illness, major psychiatric illness or substance abuse, history of cerebral vascular disease, neurological disorder, and administration of psychotropic medication. The control groups (CON) consisted of angiographed individuals undergoing surgery for heart valvular diseases and those who may have reported with chest pain but were established to have no significant coronary stenosis by angiography. Furthermore, these individuals were free of the traits (HTN or T2DM) under consideration. Exclusion criteria for this group were, among others, diseases such as cancer, autoimmune disease, or any other disorders likely to interfere with variables under investigation. This study was performed in accordance with the regulations laid down by the Hospital Ethics Committee and in accordance with the principles of the Declaration of Helsinki as well as Title 45, Part 46 of the USA code of Federal Regulation on Protection of Human Subjects. All participants signed an informed consent.Table 1Demographics of the type 2 diabetes study population.ControlCasesAllMaleFemaleAllMaleFemaleT2D20741316 (0.63)758 (0.37)25761728 (67.1)848 (32.9)Age50.3 ± 16.751.9 ± 16.347.5 ± 17.159.6 ± 11.459.5 ± 11.459.7 ± 11.4BMI28.0 ± 6.127.3 ± 5.529.3 ± 6.830.0 ± 5.828.8 ± 5.132.4 ± 6.5CAD771632 (0.82)139 (0.18)16531227 (0.74)426 (0.26)MI1069832 (0.78)237 (0.22)20041443 (0.72)561 (0.28)HTN1400912 (0.65)488 (0.35)23321539 (0.66)793 (0.34)IHDL730570 (0.78)160 (0.22)1225937 (0.76)288 (0.24)hTG372293 (0.79)79 (0.21)813550 (0.68)263 (0.32)hChol595412 (0.69)183 (0.31)1108714 (0.64)394 (0.36)OBS690366 (0.53)324 (0.47)1127621 (0.55)506 (0.45)Smokers771737 (0.96)34 (0.04)1003964 (0.96)39 (0.04)[^1]Table 2Demographics of the primary hypertension study population.ControlCasesAllMaleFemaleAllMaleFemaleHTN918593 (0.65)325 (0.35)37322451 (0.66)1281 (0.34)Age45.2 ± 16.546.9 ± 16.042.0 ± 17.157.9 ± 13.158.4 ± 12.857.0 ± 13.7BMI27.6 ± 6.127.1 ± 5.828.5 ± 6.529.5 ± 5.928.4 ± 5.231.5 ± 6.7CAD280239 (0.85)41 (0.15)21441620 (0.76)524 (0.24)MI401330 (0.82)71 (0.18)26721945 (0.73)727 (0.27)T2D244189 (0.77)55 (0.23)23321539 (0.66)793 (0.34)IHDL333266 (0.80)67 (0.20)16221241 (0.77)381 (0.23)hTG173140 (0.81)33 (0.19)1012703 (0.69)309 (0.31)hChol206152 (0.74)54 (0.26)1497974 (0.65)523 (0.35)OBS284159 (0.56)125 (0.44)1533828 (0.54)705 (0.46)Smokers356342 (0.96)14 (0.04)14181359 (0.96)59 (0.04)[^2]

2.2. Association studies {#s0020}
------------------------

In all, eight SNPs (1) rs10738607, (2) rs564398, (3) rs1412829, (4) rs10120688, (5) rs4977756, (6) rs10757274, (7) rs4977574 and (8) rs1333045 at the *CDKN2B* gene locus were selected for the association study. Selection of the SNPs of interest was based on the findings of the previous GWAS study in which several of these variants had shown either significant or borderline association with CAD/MI ([@b0225]). In the present study, their association with disease was evaluated using the Applied Biosystems Real-time PCR system (ABI Inc. CA, USA). Genotyping was accomplished by Taqman chemistry on the ABI Prism 7900HT Sequence Detection System. Primers and the TaqMan fluorogenic probes bearing a suitable reporter dye on the 5′-end and a quencher dye on the 3′-end were designed using the Primer Express software V2.0 (ABI Inc., Foster City, CA, USA) and procured from Applied Biosystems (ABI, Warrington, UK). One probe (allele 1) was labeled with VIC dye and the other (allele 2) with FAM dye at the 5′-end, and serial dilutions were run to determine the optimal working concentration. For each reaction, a 25 μl reaction was prepared by mixing 5 μl containing 50 ng DNA, 12.5 μl of 2x Universal mix (Eurogentec, Liege Science Park, 4102 Seraing, Belgium), 1.25 μl of 20x probe Assay mix and 6.25 μl DNase-free distilled water. Three no-template controls were included in each plate for normalization of emission signal. The thermal profile for the first cycle amplification was set at 50 °C for 2 min, and 95 °C for 10 min, followed by 40 cycles of 94 °C for 15 sec and 60 °C for 30 sec. The plates were then scanned for FRET signal using the 7900HT sequence detection system and data analyzed using SDS 2.0 software (Applied Biosystems, Foster City, CA, USA).

2.3. Statistical analysis {#s0025}
-------------------------

Comparison of genotypes and alleles between the cases and controls for continuous dependent variables was achieved by Analysis of Variance (ANOVA) or Student's test as appropriate. Categorical variables were analyzed by Chi-Square test, and logistic regression analysis was used to compute odds ratios and their 95% confidence intervals. All other statistical analyses were performed using the SPSS software version 14 (SPSS Inc., Chicago, USA), and data are expressed as mean ± SEM. Associations with a two-tailed *p* \< 0.05 was considered statistically significant.

3. Results {#s0030}
==========

In all, a total of 8 SNPs (1) rs10738607_A\>G, (2) rs564398_A\>G, (3) rs1412829_C\>TG, (4) rs10120688_A\>G (5) rs4977756_A\>G, (6) rs10757274, (7) rs4977574_A\>G and (8) rs1333045_C\>T at the *CDKN2B* locus were investigated for T2DM and HTN. The first analysis was performed in 2576 T2DM versus 2074 controls ([Table 1](#t0005){ref-type="table"}). Multiple regression analysis for HTN demonstrated that two of these SNPs, the rs10757274_A \[0.92 (0.84--1.00; p = 0.042\], rs1333045_T \[0.92 (0.84--1.00); p = 0.048\] were initially significantly associated T2DM. However, both lost this association after multivariate adjustments for CAD, HTN and MI. The second analysis was done in 3732 HTN versus 918 controls ([Table 2](#t0010){ref-type="table"}). None of the studied variable was significantly associated with the disease, except the rs10757274_A \[0.91(0.82--1.01; p = 0.075\] showed only borderline association in the univariate analysis. These analyses are summarized in [Table 3](#t0015){ref-type="table"}.Table 3CDKN2B polymorphism in type 2 diabetes mellitus and hypertension.Type 2 diabetes (Cases = 2576; controls 2074)SNP IDGenotypeCasesControlsUnivariate analysisMultivariate analysisOR(95%C.I.)P-valueOR(95%C.I.)P-valuers10757274_G\>AG64.462.30.915 (0.840--0.997)0.0421.022 (0.932--1.121)0.638A35.637.7rs1333045_C\>TC54.852.60.918 (0.843--0.999)0.0480.962 (0.878--1.055)0.410T45.247.4  **Hypertension** (Cases = 3732; controls = 918)rs10757274_G\>AG63.961.60.908 (0.816--1.010)0.0751.073 (0.957--1.202)0.227A36.138.4[^3]

4. Discussion {#s0035}
=============

The present study tested the likelihood that the *CDKN2B* gene on chromosome p9.21 constitutes a risk for type 2 diabetes and hypertension, two important risk traits for CAD/MI. Eight SNPs were selected for the study. These SNPs had been linked with CAD/MI in the same population in a recent GWAS by [@b0225]. In that study, among the most significantly associated SNPs were the two variants, the rs10757274 and rs1333045. Interestingly, in the present study these two were only weakly associated with T2DM, while the former showed borderline activity with HTN. Nonetheless, although multivariate analysis indicated lack of an independent association with these two diseases, it cannot be ruled out that the genomic region might indeed be involved in their manifestation. However, in light of our present findings, the fact that these variants show weak associations in our population may also be a reflection of ethnic specificity in the way genomic changes may influence disease in general.

To begin with, the genomic locus of the *CDKN2A/B* gene on chromosome 9p21 has been associated not only with CAD/MI, but other cardiovascular risk traits such as higher coronary artery calcium levels hypertension, ischemic stroke, T2DM visceral and subcutenous fat ([@b0065], [@b0080], [@b0135], [@b0170], [@b0175], [@b0130], [@b0220], [@b0240], [@b0105], [@b0230], [@b0245], [@b0155], [@b0140], [@b0125], [@b0095], [@b0090], [@b0040], [@b0030], [@b0010], [@b0150], [@b0180], [@b0190], [@b0185], [@b0260]). Notably also while, in general the gene has been associated with T2DM, these observations have been partly refuted by other studies ([@b0110], [@b0165], [@b0050], [@b0025], [@b0055]). Besides, the rs10757274 has also been linked to diseases, such as acute coronary syndrome, hypertension, stroke in hypertensive patients, metabolic syndrome, T2DM, ischemic stroke in different ethnic groups ([@b0220], [@b0095], [@b0260], [@b0250], [@b0255], [@b0200], [@b0115]). The suggestions that it may be linked to T2DM or stoke in hypertensive individuals seems to indicate that indeed it may influence pathways leading to these diseases. Similarly, although the rs1333045 was only weakly linked with T2DM, a number of studies have implicated in CAD ([@b0225]); aneurysmal subarachnoid haemorrhage ([@b0160]) and some subtypes of intercranial aneurysma ([@b0150]). These observations furnish support for the notion that this *CDKN2B* genomic region harbours gene/gene variants that are involved in disease manifestation of various cardiovascular risk traits. Besides, several SNPs that predict CAD events appear to involve pathways not currently indexed by the known or emerging risk factors, as well as those involved changes in blood lipids, for example. Thus, this overlapping association of SNPs with multiple risk factors at this locus points the existence of shared points of regulation for these phenotypes. One suggestion has been that that several cardiovascular disease-associated SNPs at this locus affect the expression of ANRIL, which, in turn modulate cell growth, possibly via CDKN2A/B regulation ([@b0045]); macrovascular complications ([@b0195]) influences vascular smooth muscle proliferation ([@b0145]) and heart failure ([@b0235]). Similarly, the weak association found in this study seems to suggest that these associations may be influence by other factor sharing these pathways. The calls for replication of such studies to exploit further the possible mechanism underlying these regulatory junctions.

In summary, the present study detected some weak link of variants on the CDKN2B locus with two important risk factors for CAD in Saudi Arabs, possibly suggesting that this locus may not directly pause risk for T2DM or HTN at least in the same way as it does to CAD/MI manifestation.
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[^1]: Numbers in brackets represent percentages within a group. CAD, coronary artery disease; BMI, body mass index; FH, family history; OBS, obesity; hChol, hypercholesterolaemia; hTG, hypertriglyceridemia; HTN, hypertension; lHDL, low high density lipoprotein; MI, myocardial infarction; T2D, type 2 diabetes mellitus.

[^2]: Numbers in brackets represent percentages within a group. CAD, coronary artery disease; BMI, body mass index; FH, family history; OBS, obesity; hChol, hypercholesterolaemia; hTG, hypertriglyceridemia; HTN, hypertension; lHDL, low high density lipoprotein; MI, myocardial infarction; T2D, type 2 diabetes mellitus.

[^3]: The table displays the variations that were linked with type 2 diabetes mellitus and hypertension; Each SNP was entered into multivariate analysis including coronary heart disease and myocardial infarction hypertension (for type 2 diabetes) and vice versa. OR, odds ratio; C.I., confidence interval.
